Pandorum Technologies raises $18M series B led by Protons Corporate

Pandorum Technologies, a biotechnology company focused on programmable regenerative medicine, has raised $18 million in a Series B funding round to advance clinical development and expand global operations.

The round was led by Protons Corporate, with participation from Galentic Pharma, investor Ashish Kacholia, Noblevast Advisory and Avinya Fund, the Burman Family, and others. Bandana Kankani, advisor and investor at Pandorum, guided the transaction.

The Bengaluru-based company, which operates in India and the United States, said the financing will support the development of therapies and help scale manufacturing across the US, Japan, and the Middle East.

Founded by Tuhin Bhowmick and Arun Chandru, Pandorum Technologies is a tissue engineering and regenerative medicine company that designs therapeutic products that aim to alleviate the health conditions of patient’s suffering from on corneal dystrophies, lung-related disorders, and liver diseases.

The company has adopted a distributed manufacturing strategy. It has partnered with AGC Biologics in Italy to serve the US and European markets and is collaborating with Nucelion Therapeutics, a subsidiary of Bharat Biotech in India, to support supply across Asia-Pacific. It is also exploring potential partnerships in the Middle East.

Pandorum’s lead focus is on ocular surface diseases, including Stevens–Johnson Syndrome and Neurotrophic Keratitis.

Beyond ophthalmology, Pandorum said it plans to expand its tunable exosome platform to target systemic inflammatory and degenerative diseases affecting the lung, liver and nervous system.

Pandorum has also developed a platform that combines biology, engineering, and computation to create therapies designed to reprogram pathological tissue states such as inflammation and fibrosis.

“Just like the Ship of Theseus, the human body is constantly being rebuilt. Pandorum focuses on restoring biological memory, redefining regenerative medicine at its core,” said Tuhin Bhowmick, Co-founder and Chief Executive Officer of Pandorum.

“Our approach treats tissue health, disease, and degeneration as a navigational challenge within an information-constrained biological landscape,” he added.

“This funding would enable us to translate breakthrough science into programmable, disease-modifying therapies, beginning with single-tissue applications and scaling to multi-tissue repair, aligned with Pandorum’s vision- to heal fast and age slow.”